Entry Point Capital, LLC Immunome Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding IMNM
# of Institutions
121Shares Held
47.1MCall Options Held
322KPut Options Held
1.91M-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.76MShares$60.7 Million0.05% of portfolio
-
Redmile Group, LLC San Francisco, CA4.89MShares$51.5 Million4.67% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA3.88MShares$40.9 Million2.46% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$39.6 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.49MShares$36.8 Million0.03% of portfolio
About Immunome Inc.
- Ticker IMNM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 12,127,400
- Market Cap $128M
- Description
- Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...